Merck & Company Inc (MRK)vsTransMedics Group Inc (TMDX)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
TMDX
TransMedics Group Inc
$98.57
-2.66%
HEALTHCARE · Cap: $3.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10637% more annual revenue ($65.01B vs $605.49M). TMDX leads profitability with a 31.4% profit margin vs 28.1%. MRK trades at a lower P/E of 15.2x. TMDX earns a higher WallStSmart Score of 64/100 (C+).
MRK
Buy59
out of 100
Grade: C
TMDX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+56.8%
Fair Value
$308.61
Current Price
$98.57
$210.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Every $100 of equity generates 54 in profit
Keeps 31 of every $100 in revenue as profit
Revenue surging 32.2% year-over-year
Earnings expanding 1188.0% YoY
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : TMDX
The strongest argument for TMDX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 13.2%. Revenue growth of 32.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TMDX
The primary concerns for TMDX are Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while TMDX is a growth play — different risk/reward profiles.
TMDX carries more volatility with a beta of 2.08 — expect wider price swings.
TMDX is growing revenue faster at 32.2% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
TMDX scores higher overall (64/100 vs 59/100), backed by strong 31.4% margins and 32.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →TransMedics Group Inc
HEALTHCARE · MEDICAL DEVICES · USA
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?